1369256-71-2Relevant academic research and scientific papers
Tetracyclic pyrimidinone compound, preparation method, composition and application thereof
-
, (2021/03/31)
A tetracyclic pyrimidinone compound represented by a formula (I) or a pharmaceutically acceptable salt thereof has a structure represented by a formula (I), is a brand new Lp-PLA2 inhibitor, and can be used for treating neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis and thelike.
Tricyclic pyrimidone compounds, preparation methods thereof, compositions thereof and uses
-
, (2022/01/08)
A tricyclic pyrimidone compound shown in formula (I) or its tautomer, racemic racemate, enantiomer, diastereomer, or mixture thereof, or a pharmaceutically acceptable salt thereof, having a structure shown in formula (I), is a brand new Lp-PLA2 inhibitor that can be used to treat neurodegenerative-related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis.
Tricyclic dihydroimidazopyrimidinone derivative, and preparation method, pharmaceutical composition and application thereof
-
Paragraph 0425-0428; 0429; 0431, (2021/05/12)
The invention provides a compound as shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the compound as aLp-PLA2 inhibitor, wherein R1, R2, Rx, Ra, Q, U, X, Y, m, n and A are defined in the specification.
PYRIMIDONE COMPOUNDS USED AS LP-PLA2 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS THEREOF
-
Paragraph 0119; 0121; 0125, (2017/11/18)
The present invention relates to pyrimidone compounds used as Lp-PLA2 inhibitors and pharmaceutical compositions thereof. The structure of the pyrimidone compounds is represented by general formula (I), wherein R1, R2, Rs
Discovery of a Novel Series of Imidazo[1,2-a]pyrimidine Derivatives as Potent and Orally Bioavailable Lipoprotein-Associated Phospholipase A2 Inhibitors
Chen, Xinde,Xu, Wenwei,Wang, Kai,Mo, Mingguang,Zhang, Wei,Du, Lili,Yuan, Xiaojing,Xu, Yechun,Wang, Yiping,Shen, Jianhua
supporting information, p. 8529 - 8541 (2015/11/24)
Inhibition of lipoprotein-associated phospholipase A2 (Lp-PLA2) has been suggested to be a promising therapeutic strategy for several inflammation-associated diseases, including atherosclerosis, Alzheimer's disease, and diabetic macu
BICYCLIC PYRIMIDONE COMPOUNDS
-
, (2014/07/08)
The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
2,3-DIHYDROIMIDAZO[1 ,2-c] PYRIMIDIN-5(1 H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS
-
Paragraph 0178; 0185, (2014/07/08)
Disclosed are 2,3-dihydroimidazo[1,2-c]pyrimidin-5(1H)-one compounds that inhibit Lp-PLA2, processes for their preparation, compositions containing them and their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2
-
Page/Page column 25; 28-29, (2014/08/07)
The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
BICYCLIC PYRIMIDONE COMPOUNDS
-
, (2013/03/26)
The present invention relates to novel bicyclic pyrimidone compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease.
